Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2017 | 3 |
2023 | 1 |
2024 | 0 |
Search Results
4 results
Results by year
Filters applied: . Clear all
Page 1
Investigation of the effects of porosity and volume fraction on the atomic behavior of cancer cells and microvascular cells of 3DN5 and 5OTF macromolecular structures during hematogenous metastasis using the molecular dynamics method.
Comput Biol Med. 2023 May;158:106832. doi: 10.1016/j.compbiomed.2023.106832. Epub 2023 Apr 5.
Comput Biol Med. 2023.
PMID: 37037148
Unique Features of Germline Variation in Five Egyptian Familial Breast Cancer Families Revealed by Exome Sequencing.
Kim YC, Soliman AS, Cui J, Ramadan M, Hablas A, Abouelhoda M, Hussien N, Ahmed O, Zekri AN, Seifeldin IA, Wang SM.
Kim YC, et al.
PLoS One. 2017 Jan 11;12(1):e0167581. doi: 10.1371/journal.pone.0167581. eCollection 2017.
PLoS One. 2017.
PMID: 28076423
Free PMC article.
Clinical Trial.
Item in Clipboard
Predictive Control of the Blood Glucose Level in Type I Diabetic Patient Using Delay Differential Equation Wang Model.
Esna-Ashari M, Zekri M, Askari M, Khalili N.
Esna-Ashari M, et al.
J Med Signals Sens. 2017 Jan-Mar;7(1):8-20.
J Med Signals Sens. 2017.
PMID: 28487828
Free PMC article.
Consequently, this method can decrease the risk of hypoglycemia, a lethal phenomenon in regulating BG level in diabetes caused by a low BG level. Two delay differential equation models, namely Wang model and Enhanced Wang model, are applied as controller model and p …
Consequently, this method can decrease the risk of hypoglycemia, a lethal phenomenon in regulating BG level in diabetes caused by a low BG l …
Item in Clipboard
Safety and tolerability of subcutaneous trastuzumab for the adjuvant treatment of human epidermal growth factor receptor 2-positive early breast cancer: SafeHer phase III study's primary analysis of 2573 patients.
Gligorov J, Ataseven B, Verrill M, De Laurentiis M, Jung KH, Azim HA, Al-Sakaff N, Lauer S, Shing M, Pivot X; SafeHer Study Group.
Gligorov J, et al.
Eur J Cancer. 2017 Sep;82:237-246. doi: 10.1016/j.ejca.2017.05.010. Epub 2017 Jun 16.
Eur J Cancer. 2017.
PMID: 28625777
Clinical Trial.
Item in Clipboard
Cite
Cite